[go: up one dir, main page]

WO2011058367A3 - Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor - Google Patents

Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor Download PDF

Info

Publication number
WO2011058367A3
WO2011058367A3 PCT/GB2010/051888 GB2010051888W WO2011058367A3 WO 2011058367 A3 WO2011058367 A3 WO 2011058367A3 GB 2010051888 W GB2010051888 W GB 2010051888W WO 2011058367 A3 WO2011058367 A3 WO 2011058367A3
Authority
WO
WIPO (PCT)
Prior art keywords
parp
treatment
adp
ribose
polymerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/051888
Other languages
French (fr)
Other versions
WO2011058367A2 (en
Inventor
Jonathan Richard Dry
Christopher George Harbron
Darren Richard Hodgson
Alan Yin Kai Lau
Mark James O'connor
John Edward Prime
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2011058367A2 publication Critical patent/WO2011058367A2/en
Publication of WO2011058367A3 publication Critical patent/WO2011058367A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates generally to methods for treating cancer and to methods of predicting the responsiveness of a cancer cell to therapeutic treatment. In particular, the invention provides the identities of genes (biomarkers) that may be used to identify populations or individuals of cancer sufferers that are likely to respond favourably to treatment with a Poly (ADP - Ribose) polymerase (PARP) inhibitor. In a preferred embodiment, the expression levels of at least one base excision repair biomarker from Table 1 (including at least PARP-1), at least one homologous recombination biomarker from Table 2 and at least one proliferation biomarker from Table 3 are measured.
PCT/GB2010/051888 2009-11-13 2010-11-11 Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor Ceased WO2011058367A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26093409P 2009-11-13 2009-11-13
US61/260,934 2009-11-13

Publications (2)

Publication Number Publication Date
WO2011058367A2 WO2011058367A2 (en) 2011-05-19
WO2011058367A3 true WO2011058367A3 (en) 2011-08-18

Family

ID=43500036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/051888 Ceased WO2011058367A2 (en) 2009-11-13 2010-11-11 Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor

Country Status (1)

Country Link
WO (1) WO2011058367A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637798B2 (en) 2013-05-21 2017-05-02 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
EP2710142B1 (en) * 2011-05-18 2017-04-26 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of cancer aggressiveness and genetic instability
WO2013133876A1 (en) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer
EP4462120A3 (en) * 2012-02-23 2025-01-08 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
WO2014138101A1 (en) * 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
US20160138114A1 (en) * 2013-06-19 2016-05-19 The Regents Of The University Of California Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
WO2015042570A1 (en) 2013-09-23 2015-03-26 The University Of Chicago Methods and compositions relating to cancer therapy with dna damaging agents
EP3137076A4 (en) * 2014-05-02 2017-12-06 Emory University Selective chemotherapy treatments and diagnostic methods related thereto
US10823738B2 (en) * 2015-12-07 2020-11-03 George Mason Research Foundation, Inc. Methods for breast cancer treatment
AU2017290244B2 (en) 2016-06-29 2023-03-02 Tesaro, Inc. Methods of treating ovarian cancer
WO2018161081A1 (en) * 2017-03-03 2018-09-07 Board Of Regents, The University Of Texas System Gene signatures to predict drug response in cancer
CA3059576A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1 (sra737)/parpi combination methods of inhibiting tumor growth
WO2019063004A1 (en) * 2017-09-30 2019-04-04 浙江数问生物技术有限公司 Application of dna recombination proficiency score (rds) in cancer treatment
SG11202006147SA (en) * 2017-12-27 2020-07-29 Tesaro Inc Methods of treating cancer
EP4552696A3 (en) * 2018-05-15 2025-11-05 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US20210093730A1 (en) * 2019-10-01 2021-04-01 Immunomedics, Inc. Biomarkers for antibody-drug conjugate monotherapy or combination therapy
GB202103080D0 (en) * 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN114934120A (en) * 2022-06-20 2022-08-23 柳州市人民医院 Application of circular RNA marker for rapidly identifying early colorectal cancer and diagnostic kit
JPWO2024009946A1 (en) * 2022-07-08 2024-01-11

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
JPH0314319A (en) 1989-06-13 1991-01-23 Anritsu Corp Ladder resistor circuit
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6285701B1 (en) 1998-08-06 2001-09-04 Lambda Physik Ag Laser resonator for improving narrow band emission of an excimer laser
DE60009033T2 (en) 1999-01-11 2004-08-05 Agouron Pharmaceuticals, Inc., La Jolla TRICYCLIC INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASES
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (en) 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES
WO2001021615A1 (en) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
CN1374961A (en) 1999-09-28 2002-10-16 巴斯福股份公司 Azaindole derivatives, their preparation and applications
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
EP1257551B1 (en) 2000-02-01 2007-09-05 Abbott GmbH & Co. KG Heterocyclic compounds and their use as parp inhibitors
WO2001079184A1 (en) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (en) 2000-05-11 2001-11-15 Basf Ag New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
IL155645A0 (en) 2000-10-30 2003-11-23 Kudos Pharm Ltd Phthalazinone derivatives
ITMI20002358A1 (en) 2000-10-31 2002-05-01 Flavio Moroni TIENO DERIVATIVES, 2, 3-C | ISOCHINOLIN-3-ONE AS INHIBITORS OF POLY (DP-RIBOSE) POLYMERASE
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
WO2002068407A1 (en) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
AU2002358650A1 (en) 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
DE60336890D1 (en) 2002-02-19 2011-06-09 Ono Pharmaceutical Co CONDENSED PYRIDAZINE DERIVATIVE COMPOUNDS AND THE COMPOUNDS CONTAINING ACTIVE SUBSTANCES
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
WO2004014873A1 (en) 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof
AU2003264386A1 (en) 2002-09-10 2004-04-30 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
AU2003284632A1 (en) 2002-11-22 2004-06-18 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
CN100398519C (en) 2003-02-28 2008-07-02 伊诺泰克制药公司 Tetracyclic benzamide derivatives and their usage
KR101146806B1 (en) 2003-03-12 2012-05-22 메이브릿지 리미티드 Phthalazinone derivatives
MXPA05010563A (en) 2003-03-31 2005-11-23 Pfizer Salts of tricyclic inhibitors of poly(adp-ribose) polymerases.
HU0301154D0 (en) 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
HU227948B1 (en) 2003-04-30 2012-07-30 Pecsi Tudomanyegyetem Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
ES2396334T3 (en) 2003-05-28 2013-02-20 Eisai Inc. Compounds, methods and pharmaceutical compositions for PARP inhibition
WO2004108723A1 (en) 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors
NZ544989A (en) 2003-07-25 2009-10-30 Cancer Rec Tech Ltd Tricyclic PARP inhibitors
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
CA2537097A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
US7855207B2 (en) 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
WO2005054209A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-­ribose) polymerase inhibitors
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
ES2551299T3 (en) 2003-12-05 2015-11-17 Janssen Pharmaceutica Nv 2-Quinolinones and 6-substituted 2-quinoxalinones as poly (ADP-ribose) polymerase inhibitors
EP1694653B1 (en) 2003-12-10 2016-01-20 Janssen Pharmaceutica NV 6-(hetero-)cyclohexylalkyl substituted 2-quinolinones/2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
PE20060285A1 (en) 2004-03-30 2006-05-08 Aventis Pharma Inc PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS
DE102004028973A1 (en) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituted tetrahydro-2H-isoquinolin-1-one derivatives, process for their preparation and their use as medicaments
MXPA06014541A (en) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Quinazolinedione derivatives as parp inhibitors.
WO2006003146A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
US7803795B2 (en) 2004-06-30 2010-09-28 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
DE102004050196A1 (en) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituted 2-pyridone derivatives, process for their preparation and their use as medicaments
US20060204981A1 (en) 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
CA2595290C (en) 2005-01-19 2013-06-25 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP2038654A4 (en) 2006-06-12 2010-08-11 Bipar Sciences Inc Method of treating diseases with parp inhibitors
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
UY31603A1 (en) 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALMEIDA ET AL: "A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification", DNA REPAIR, vol. 6, no. 6, 3 May 2007 (2007-05-03), ELSEVIER, AMSTERDAM, NL, pages 695 - 711, XP022059296, ISSN: 1568-7864, DOI: 10.1016/J.DNAREP.2007.01.009 *
ANONYMUS: "PARP Inhibitors (future cancer therapy) and the importance of molecular pathology", 16 September 2009 (2009-09-16), XP002620580, Retrieved from the Internet <URL:www.innovationandchoice.com/2009/09/16/parp-inhibitors-future-cancer-therapy-and-the-importance-of-molecular-pathology> [retrieved on 20110202] *
BRUCE JAMES W ET AL: "The host cell sulfonation pathway contributes to retroviral infection at a step coincident with provirus establishment.", PLOS PATHOGENS, vol. 4, no. 11, E1000207, November 2008 (2008-11-01), pages 1 - 15, XP002620581, ISSN: 1553-7374 *
DAMIA ET AL: "Targeting DNA repair as a promising approach in cancer therapy", EUROPEAN JOURNAL OF CANCER, vol. 43, no. 12, 11 August 2007 (2007-08-11), PERGAMON PRESS, OXFORD, GB, pages 1791 - 1801, XP022196531, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2007.05.003 *
DRY JONATHAN R ET AL: "Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 51, 21 April 2010 (2010-04-21), AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, pages 848 - 849, XP009143942, ISSN: 0197-016X *
LORD C J ET AL: "A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity", DNA REPAIR, vol. 7, no. 12, 1 December 2008 (2008-12-01), ELSEVIER, AMSTERDAM, NL, pages 2010 - 2019, XP025627852, ISSN: 1568-7864, [retrieved on 20081015], DOI: 10.1016/J.DNAREP.2008.08.014 *
MCCABE NUALA ET AL: "Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition", CANCER RESEARCH, vol. 66, no. 16, 15 August 2006 (2006-08-15), AMERICAN ASSOCIATION FOR CANCER REREARCH, US, pages 8109 - 8115, XP002482543, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-0140 *
PERALTA-LEAL A ET AL: "PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases", FREE RADICAL BIOLOGY AND MEDICINE, vol. 47, no. 1, 1 July 2009 (2009-07-01), ELSEVIER SCIENCE, US, pages 13 - 26, XP026158945, ISSN: 0891-5849, [retrieved on 20090410], DOI: 10.1016/J.FREERADBIOMED.2009.04.008 *
TURNER NICHOLAS C ET AL: "A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor", EMBO JOURNAL, vol. 27, no. 9, 1 May 2008 (2008-05-01), OXFORD UNIVERSITY PRESS, SURREY, GB, pages 1368 - 1377, XP002498071, ISSN: 0261-4189, [retrieved on 20080403], DOI: 10.1038/EMBOJ.2008.61 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637798B2 (en) 2013-05-21 2017-05-02 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer

Also Published As

Publication number Publication date
WO2011058367A2 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
WO2011058367A3 (en) Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
NZ620799A (en) Molecular diagnostic test for cancer
MX2009002936A (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors.
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
WO2006135886A3 (en) Compositions and methods for treating and diagnosing cancer
WO2011160063A3 (en) Methods and materials for assessing loss of heterozygosity
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2385062A3 (en) Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
HK1199068A1 (en) Identification of gene expression profile as a predictive biomarker for lkb1 status
MX2012001716A (en) Biological markers for monitoring patient response to vegf antagonists.
EP3211094A3 (en) Methods for treating, diagnosing, and monitoring rheumatoid arthritis
MX350723B (en) Il-1 binding proteins.
WO2012138783A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
MX2011009690A (en) Methods and compositions for cell-proliferation-related disorders.
WO2008128169A8 (en) Sparc and methods of use thereof
WO2007093657A3 (en) Method for the molecular diagnosis of prostate cancer and kit for implementing same
WO2009131887A3 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
WO2008109423A8 (en) Multigene assay to predict outcome in an individual with glioblastoma
EP2522743A3 (en) Genetic variants contributing to risk of prostate cancer
WO2007027509A3 (en) Evaluating and treating scleroderma
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
WO2009114756A3 (en) Biomarkers for inflammatory bowel disease and irritable bowel syndrome
NZ589251A (en) Novel marker for detection of bladder cancer
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782357

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10782357

Country of ref document: EP

Kind code of ref document: A2